Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
7 pending office actions • 1 art units • 7 examiners • 0 of 7 (0%) have an AI response strategy ready
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §102 only | 1 (14%) |
| §112 only | 1 (14%) |
| Double-patenting only | 1 (14%) |
| Double-patenting + other | 3 (43%) |
| Multi-statute (no §101) | 1 (14%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ROZOF, TIMOTHY R | 1 | 72.7% | +23.8% |
| RZECZYCKI, PHILLIP MATTHEW | 1 | 64.8% | +37.0% |
| SAEED, KAMAL A | 1 | 83.8% | +9.8% |
| BRAUN, MADELINE E | 1 | 68.7% | +24.6% |
| HABTE, KAHSAY | 1 | 85.0% | +7.4% |
| KUCHARCZK, JED A | 1 | 80.2% | +16.7% |
| AULAKH, CHARANJIT | 1 | 80.6% | -14.5% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18799146 | DELIVERY OF THERAPEUTIC ALKALOID COMPOUNDS | SAEED, KAMAL A | — |
| 18799037 | THERAPEUTIC ALKALOID COMPOUNDS | HABTE, KAHSAY | — |
| 18711184 | SOLID FORMS OF MESEMBRINE AND THERAPEUTIC USES THEREOF | KUCHARCZK, JED A | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18705706 | DEUTERATED FORMS OF ALKALOID COMPOUNDS AND THERAPEUTIC USES THEREOF | AULAKH, CHARANJIT | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18812309 | THERAPEUTIC ALKALOID COMPOUNDS | ROZOF, TIMOTHY R | — |
| 18806984 | DELIVERY OF THERAPEUTIC ALKALOID COMPOUNDS | RZECZYCKI, PHILLIP MATTHEW | — |
| 18799074 | ALKYL-SUBSTITUTED DERIVATIVES OF MESEMBRINE AND MESEMBRENONE AND THERAPEUTIC USES THEREOF | BRAUN, MADELINE E | — |
| 18711184 | SOLID FORMS OF MESEMBRINE AND THERAPEUTIC USES THEREOF | KUCHARCZK, JED A | — |
| Art Unit | Apps |
|---|---|
| 1621 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18812309 | THERAPEUTIC ALKALOID COMPOUNDS | ROZOF, TIMOTHY R | — | §102DP | Non-Final OA | — | Pending | Aug 22, 2024 |
| 18806984 | DELIVERY OF THERAPEUTIC ALKALOID COMPOUNDS | RZECZYCKI, PHILLIP MATTHEW | — | §103§112DP | Non-Final OA | — | Pending | Aug 16, 2024 |
| 18799146 | DELIVERY OF THERAPEUTIC ALKALOID COMPOUNDS | SAEED, KAMAL A | — | DP | Non-Final OA | — | Pending | Aug 09, 2024 |
| 18799074 | ALKYL-SUBSTITUTED DERIVATIVES OF MESEMBRINE AND MESEMBRENONE AND THERAPEUTIC USES THEREOF | BRAUN, MADELINE E | — | §103DP | Non-Final OA | — | Pending | Aug 09, 2024 |
| 18799037 | THERAPEUTIC ALKALOID COMPOUNDS | HABTE, KAHSAY | — | §112 | Non-Final OA | — | Pending | Aug 09, 2024 |
| 18711184 | SOLID FORMS OF MESEMBRINE AND THERAPEUTIC USES THEREOF | KUCHARCZK, JED A | — | §102 | Non-Final OA | — | Pending | May 17, 2024 |
| 18705706 | DEUTERATED FORMS OF ALKALOID COMPOUNDS AND THERAPEUTIC USES THEREOF | AULAKH, CHARANJIT | 1621 | §102§112 | Non-Final OA | — | Pending | Apr 29, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial